Circulating Tumor DNA Evaluated by Next-Generation Sequencing Is Predictive of Tumor Response and Prolonged Clinical Benefit With Nivolumab in Advanced Non-Small Cell Lung Cancer

OncoImmunology - United States
doi 10.1080/2162402x.2018.1424675

Related search